Invest. Engage. Save.

Rss

Moving Forward

Posted by: BIO Ventures for Global Health on 6/28/2010 | 1 Comment
Last week BVGH CEO Melinda Moree attended a meeting in Brussels called by the European Union on Global Health. These high-level meetings seem largely ceremonial but obtaining consensus and inter-governmental agreement is key to enabling large organizations to move forward. So, they are frustrating but necessary.
Categories: Meetings

Coming Out of the Dark

Posted by: BIO Ventures for Global Health on 6/21/2010 | 2 Comments
Last Wednesday, I had the opportunity to see Ricardo Preve’s documentary “Chagas: A Hidden Affliction” at a screening in Washington, DC. Preve, a filmmaker who hails from the Chagas-endemic northwest region of Argentina, made this movie to raise awareness after a friend was diagnosed with the disease. I loved the film, but it brought home to me how many people are unaware of Chagas disease. The opening segment portrays individuals being approached Michael Moore-style by the camera crew in Charlottesville, VA
Categories: News

On the Market

Posted by: BIO Ventures for Global Health on 6/8/2010 | 0 Comments
In this economy, vibrant may not be the first word you think of when assessing the life sciences. The recession affected the industry worldwide, drying up venture capital funding and making lucrative IPOs a thing of the past. But things are starting to look up, and according to Prithviraj Chavan, Minister for Science and Technology and Earth Sciences of India, vibrant is exactly the word to describe today’s Indian life sciences sector.
Page:

Blog Home
  
  

Recent Comments

by simon on The Most Important Hire in Global Health
"I'd like to comment on the fact that the term "cost-effective" vaccines is not meaningful, since cost-effectiveness always depends on the Willigness to Pay of a given coutnry (which WHO recommends to be 1-3xGDP per capita). E.g. while in UK a medicines/vaccine that has incremental cost-effectiveness ratio of 43,000-130,000 USD/QALY will be considered "cost-effective", it will not be the case in India where the threshold is 1-3xGDP=1,000-3,000 USD/QALY. It means that the same vaccine would need to be 43x cheaper in India than in UK to be cost-effective. I believe that the future of developing countries will depend on their ability to develop vaccines locally and sell them at local prices. I am currently involved in a research project in India which aims at understanding the challenges of entrepreneurship and its role in affordable healthcare in the future. Best regards " Read more »

by Mark H on Trademark of Innovation
"Often the pharmaceutical companies are seen as evil because they do not do enough to help the poor by giving away medicines or licence rights. But we must consider two things: 1 they are commecial companies and have legal obligations towards their shareholders i.e. their prime concern is making money 2 these companies invest a vastly greater amount of money in R&D than the government. As a result their R&D occasionally finds cures inadvertently for other diseases - even if they are not actively trying to create the right medicine. So how do you create an incentive for the most effective creator of new innovative cures whose primary goal is to make money (like all companies)? Well the answer seems obvious - reward them with tax benefits that would help push them above their competitors. Whilst you could argue that this would prevent the government from reaping the benefits (tax) you could also say that the competition created would drive innovation and spending in the private sector which would improve the economy. A win win win situation - pharmaceuticals, government, developing countries!" Read more »

by BIO Ventures for Global Health on Ready to Go
"Thanks so much for your interest, Trudy. We are not currently working with the Carter Center but we are interested in speaking with them to gain epidemiological information for our Global Health Primer, and so hope to be working together in the future. " Read more »

  

Tag Cloud